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Treatment of focal degenerative cartilage defects with
polymer-based autologous chondrocyte grafts: four-year clinical
results
Abstract
INTRODUCTION: Second-generation autologous chondrocyte implantation with scaffolds stabilizing
the grafts is a clinically effective procedure for cartilage repair. In this ongoing prospective
observational case report study, we evaluated the effectiveness of BioSeed-C, a cell-based cartilage graft
based on autologous chondrocytes embedded in fibrin and a stable resorbable polymer scaffold, for the
treatment of clinical symptomatic focal degenerative defects of the knee. METHODS: Clinical outcome
after 4-year clinical follow-up was assessed in 19 patients with preoperatively radiologically confirmed
osteoarthritis and a Kellgren-Lawrence score of 2 or more. Clinical scoring was performed before
implantation of the graft and 6, 12, and 48 months after implantation using the Lysholm score, the Knee
injury and Osteoarthritis Outcome Score (KOOS), the International Knee Documentation Committee
(IKDC) score, and the International Cartilage Repair Society (ICRS) score. Cartilage regeneration and
articular resurfacing were assessed by magnetic resonance imaging (MRI) 4 years after implantation of
the autologous cartilage graft. RESULTS: Significant improvement (P < 0.05) of the Lysholm and ICRS
scores was observed as early as 6 months after implantation of BioSeed-C and remained stable during
follow-up. The IKDC score showed significant improvement compared with the preoperative situation
at 12 and 48 months (P < 0.05). The KOOS showed significant improvement in the subclasses pain,
activities of daily living, and knee-related quality of life 6 months as well as 1 and 4 years after
implantation of BioSeed-C in osteoarthritic defects (P < 0.05). MRI analysis showed moderate to
complete defect filling with a normal to incidentally hyperintense signal in 16 out of 19 patients treated
with BioSeed-C. Two patients without improvement in the clinical and MRI scores received a total knee
endoprosthesis after 4 years. CONCLUSIONS: The results show that the good clinical outcome
achieved 1 year after implantation of BioSeed-C remains stable over the course of a period of 4 years
and suggest that implanting BioSeed-C is a promising treatment option for the repair of focal
degenerative defects of the knee.
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Abstract
Introduction Second-generation autologous chondrocyte
implantation with scaffolds stabilizing the grafts is a clinically
effective procedure for cartilage repair. In this ongoing
prospective observational case report study, we evaluated the
effectiveness of BioSeed®-C, a cell-based cartilage graft based
on autologous chondrocytes embedded in fibrin and a stable
resorbable polymer scaffold, for the treatment of clinical
symptomatic focal degenerative defects of the knee.
Methods Clinical outcome after 4-year clinical follow-up was
assessed in 19 patients with preoperatively radiologically
confirmed osteoarthritis and a Kellgren-Lawrence score of 2 or
more. Clinical scoring was performed before implantation of the
graft and 6, 12, and 48 months after implantation using the
Lysholm score, the Knee injury and Osteoarthritis Outcome
Score (KOOS), the International Knee Documentation
Committee (IKDC) score, and the International Cartilage Repair
Society (ICRS) score. Cartilage regeneration and articular
resurfacing were assessed by magnetic resonance imaging
(MRI) 4 years after implantation of the autologous cartilage graft.
Results Significant improvement (P < 0.05) of the Lysholm and
ICRS scores was observed as early as 6 months after
implantation of BioSeed®-C and remained stable during follow-
up. The IKDC score showed significant improvement compared
with the preoperative situation at 12 and 48 months (P < 0.05).
The KOOS showed significant improvement in the subclasses
pain, activities of daily living, and knee-related quality of life 6
months as well as 1 and 4 years after implantation of BioSeed®-
C in osteoarthritic defects (P < 0.05). MRI analysis showed
moderate to complete defect filling with a normal to incidentally
hyperintense signal in 16 out of 19 patients treated with
BioSeed®-C. Two patients without improvement in the clinical
and MRI scores received a total knee endoprosthesis after 4
years.
Conclusions The results show that the good clinical outcome
achieved 1 year after implantation of BioSeed®-C remains
stable over the course of a period of 4 years and suggest that
implanting BioSeed®-C is a promising treatment option for the
repair of focal degenerative defects of the knee.
Introduction
Cartilage lesions of the knee occur frequently and represent a
major health problem. Consecutive knee arthroscopies
showed that up to 63% of the patients with knee-related
symptoms suffered from chondral or osteochondral defects
[1,2]. These defects comprise focal osteochondral or chondral
lesions in 67%, osteoarthritic defects in 29%, lesions related
to osteochondritis dissecans in 2%, and other defects in 1%
of the cases [3]. Recently, a variety of surgical techniques that
aim for resurfacing and regenerating of the articular cartilage
have evolved. In the clinical routine, debridement, bone mar-
row-stimulating techniques, osteochondral autograft transfer,
and autologous chondrocyte implantation (ACI) are commonly
used cartilage repair techniques [4-8].Page 1 of 11
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Brittberg and colleagues [4] in 1994 represents the starting
point of cell-based cartilage repair and regenerative medicine.
Up to now, more than 15,000 patients worldwide have been
treated with ACI [9], and various reports documented the clin-
ical effectiveness of implanting autologous culture-expanded
chondrocytes for cartilage repair [10-13]. Although there is no
significant evidence that ACI produces superior clinical results
for the treatment of full-thickness articular cartilage defects
compared with other cartilage repair interventions [14,15], it is
regarded as a second-line treatment for small defects and a
first-line treatment for defects larger than 2 to 4 cm2 [16].
For ACI, a small partial or full-thickness cartilage biopsy is
taken from a less weight-bearing area of the healthy articular
cartilage. The chondrocytes are harvested by enzymatic diges-
tion and cells are grown with autologous serum. For chondro-
cyte implantation, a periosteal flap or a collagen sheet is
sutured to the surrounding healthy cartilage rim, creating a res-
ervoir for the injection of the autologous chondrocyte cell sus-
pension. The need for an intact cartilage rim limits the use of
ACI to some regions of the knee, and the covering of the
chondrocyte suspension with a periosteal flap or a collagen
sheet may be insecure (for instance, in degenerative defects
that often miss an intact cartilage rim). In addition, potential
sources of complications may include periosteal hypertrophy,
loosening of the periosteal flap, ablation, and loss of cells into
the joint cavity [17-19]. These technical disadvantages of ACI
result in re-operations in up to 25% to 36% of the patients
[20,21]. Therefore, cartilage tissue engineering grafts that
address these disadvantages by using three-dimensional scaf-
folds stabilizing the graft and the regenerative potential of
autologous chondrocytes were developed. Meanwhile, clinical
results have shown the effectiveness of hyaluronan-based
[22,23], collagen-based [24,25], and resorbable polymer-
based [26] autologous chondrocyte grafts for the repair of car-
tilage defects.
Currently, ACI is contraindicated in osteoarthritic patients.
Nevertheless, preclinical studies suggest that chondrocytes or
mesenchymal stem cells from osteoarthritic patients may have
the capacity to form cartilage repair tissue and fulfill the pre-
requisites for use in ACI [27,28]. However, for cell-based car-
tilage therapies in osteoarthritis, it is important to harvest
unaffected healthy cartilage biopsies since healthy chondro-
cytes have been shown to form a cartilage tissue in vitro that
shows better morphology and a higher proteoglycan content
than chondrocytes derived from osteoarthritic joints [29]. Clin-
ically, it has been shown that microfracture treatment of
patients with moderate osteoarthritis improved their pain and
activity of daily living and significantly widened the joint spaces
1 year after treatment compared with the preoperative situa-
tion [30]. The effectiveness of a second-generation cartilage
graft based on hyaluronan has been shown for the treatment
of osteoarthritic knees with osteoarthritis not inhibiting the
regeneration sequence [31].
Recently, it was shown that the autologous cartilage graft Bio-
Seed®-C (BioTissue Technologies GmbH, Freiburg, Ger-
many) based on a bioresorbable two-component gel-polymer
scaffold is effective for the treatment of traumatic and focal
osteoarthritic cartilage defects of the knee [26]. The aim of the
present study was to evaluate ACI using BioSeed®-C for the
treatment of mild degenerative and focal osteoarthritic defects
of the knee. Magnetic resonance imaging (MRI) analysis of the
cartilage repair tissue as well as the clinical evaluation of a
series of 19 patients with pre-existing osteoarthritic symptoms
and a 4-year clinical follow-up document the effectiveness of
BioSeed®-C for the treatment of focal degenerative cartilage
defects.
Materials and methods
Patients
From December 2001 to October 2002, 79 patients with trau-
matic and degenerative chondral defects of the knee joint
were treated with a second-generation ACI (BioSeed®-C).
Patients suffered from traumatic, mild degenerative, or oste-
oarthritic and symptomatic defects of the articular cartilage of
the knee which were clinically significant [26]. The study was
performed in compliance with the ethical review board of the
University of Freiburg, Germany. All patients gave their con-
sent to participate. Radiographs were taken preoperatively,
and osteoarthritic degenerations were evaluated by two inde-
pendent observers using the Kellgren-Lawrence scoring sys-
tem. The observers were blinded to the procedure. A Kellgren-
Lawrence score of greater than or equal to 2 defines osteoar-
thritis [32] and was found in 24 patients. Nineteen patients
gave consent to a clinical follow-up of 4 years. Clinical exami-
nations were performed at 0, 6, 12, and 48 to 60 months.
Characteristics of patients with degenerative cartilage defects
are presented in Table 1. The average age of patients (8
females and 11 males; mean body mass index of 25, ranging
from 19 to 34) was 35 years (25 to 50 years). The mean defect
size of the first lesion was 4 cm2 (2 to 6 cm2). All defects (first
lesion) were classified as Outerbridge class IV [33] and were
located on the medial femoral condyle (n = 14), the lateral fem-
oral condyle (n = 2), or the patella (n = 3). Four patients had a
second chondral defect that was treated with ACI as well. Pre-
vious surgical procedures were shaving (n = 10), abrasion
arthroplasty (n = 4), drilling/microfracture (n = 1), meniscecto-
mies (n = 6), anterior cruciate ligament/collateral ligament
reconstructions (n = 7), or high tibial osteotomy (n = 5).
Implantation of BioSeed®-C and follow-up treatment
For preparation of BioSeed®-C, autologous chondrocytes
were harvested from healthy cartilage (approximately 250 mg)
of a less weight-bearing area of the knee. One hundred millili-
ters of whole blood was collected with a conventional blood-Page 2 of 11
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used for autologous chondrocyte growth. Twenty million
chondrocytes were rearranged in fibrin and a polymer-based
scaffold (2 × 3 cm and 0.2 cm in height) of polyglycolic/poly-
lactic acid (polyglactin, vicryl) and polydioxanone. After careful
debridement of the defective cartilage down to the subchon-
dral bone, the graft was fitted to the size of the defect and
implanted arthrotomically. Fixation of the graft (Figure 1) was
achieved by transosseous anchoring as described previously
[34]. Starting the day after surgery, patients were subjected to
continuous passive motion. For 6 weeks, partial loading with
15% of body weight as well as isometric tension exercises
were allowed. In weeks 7 to 12, patients increased the loading
and performed strengthening exercises and active physiother-
apy at a gentle level. From week 13 on, patients gradually
increased the weight and performed muscular and coordina-
tion exercises up to full weight-bearing. Gentle exertion was
allowed after 6 months and more strenuous activities and con-
tact sports after 12 months.
Evaluation of clinical results
For evaluation of clinical results after implantation of Bio-
Seed®-C, the Lysholm score [35], the Knee injury and Oste-
oarthritis Outcome Score (KOOS) [36], and the International
Knee Documentation Committee (IKDC) Knee Examination
Form [37] were applied. The Knee Examination Form (sur-
geons' part) of the International Cartilage Repair Society
(ICRS) cartilage injury evaluation package evaluates the sub-
groups knee joint effusion, passive motion deficit, ligaments,
compartment, harvest site pathology, joint space, and func-
tionality [38]. The score was applied and grading was per-
formed from 1 (normal) to 4 (severely abnormal). The lowest
grade within a group determines the group rate, and the worst
group grade determines the final evaluation. The clinical situa-
tion was documented before and 6, 12 as well as 48 to 60
months after implantation of the graft. Forty-eight to sixty
months after transplantation, repair and resurfacing of carti-
lage defects (n = 17) were evaluated with a state-of-the-art 1.5
Tesla MRI scanner (Siemens AG, Erlangen, Germany) and the
Henderson scoring system was applied [13]. Hypertrophic
changes were classified with the Kreuz score [19].
Table 1
Characteristics of patients with degenerative cartilage defects
Characteristic Patient data
Gender Female (n = 8), male (n = 11)
Age, years 35 (range 25–50)
Height, cm 173 (range 162–184)
Weight, kg 75 (range 57–100)
Body mass index 25 (range 19–34)
Kellgren-Lawrence score 2 (n = 10)
3 (n = 9)
Defect size of 1st lesion, cm2 4 (range 2–6)
Outerbridge classification of 1st lesion IV (n = 19)
Localization of 1st lesion Medial femoral condyle (n = 14)
Lateral femoral condyle (n = 2)
Patella (n = 3)
2nd lesion n = 4
Defect size of 2nd lesion, cm2 3 (range 2–4)
Outerbridge classification of 2nd lesion IV (n = 4)
Localization of 2nd lesion Medial femoral condyle (n = 1)
Trochlea (n = 3)
Concomitant surgeries High tibial osteotomy (n = 5)
Anterior cruciate ligament reconstruction (n = 4)
Previous surgical procedures High tibial osteotomy (n = 5)
Shaving (n = 10)
Abrasion arthroplasty (n = 4),
Microfracture/drilling (n = 1)
Meniscectomy (n = 6)
Anterior cruciate ligament/collateral ligament reconstruction (n = 7)Page 3 of 11
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For statistical analysis of the Lysholm and ICRS scores, the
Kruskal-Wallis test and the one-way analysis of variance
(ANOVA) of ranks test were used. For isolating the groups that
differed significantly (P < 0.05) from the others, the all-pair-
wise multiple comparison procedure (Dunn's method) was
applied. Statistical analysis of the IKDC data was performed
using ANOVA followed by the t test. Differences were consid-
ered significant at a P value of less than 0.05. For analysis of
the KOOS, the non-parametric Mann-Whitney rank sum test
was applied and differences were considered significant at a
P value of less than 0.05. All comparisons were performed
between scorings at every individual point in time of the follow-
up period compared with the preoperative scores.
Results
Postoperative findings in patients with focal 
degenerative cartilage defects treated with BioSeed®-C
BioSeed®-C was implanted arthrotomically using a transos-
seous fixation technique (Figure 1). The degenerated cartilage
was debrided down to the subchondral bone, and the graft
was fitted to the size of the defect. For fixation, the graft was
armed in each corner with resorbable threads forming loops
that were secured by threefold knots (Figure 1a). On every
corner of the defect, a k-wire with a thread guide was drilled
using the inside-out technique (Figure 1b). The k-wires that
carry guiding threads thread through the guide of the k-wire,
and the loops of the graft were pulled (inside-out) through the
femoral bone (Figure 1c). The threefold knots act as anchors
that seize within the subchondral bone and thus securely fix
the graft in the defect (Figure 1d).
BioSeed®-C was implanted in focal degenerative cartilage
defects of knees that showed radiological signs of osteoar-
thritic degeneration (Figure 2). Applying the Kellgren-Law-
rence score to the preoperatively performed radiographs
showed that 24 patients had osteoarthritis with a Kellgren-
Lawrence score of 2 with constriction of the joint space (Fig-
ure 2a, black arrowhead) or a score of 3 with constriction and
formation of osteophytes (Figure 2b, white arrowheads). Nine-
teen out of twenty-four patients gave consent to clinical follow-
up conducted 4 years after implantation of the graft. Postop-
eratively, no clinical signs of persistent knee joint infection or
allergic reactions were evident. Knee joint effusion or swelling
was reported by 9 patients. Symptoms of temporary blocking
were observed in 4 out of 19 patients. None of the patients
acquired potentially graft-related autoimmune disorders or
signs of hypersensitivity. There were no signs of malignant
transformation, migration of chondrocytes, poisoning, toxicity,
organ failure, hepatic or renal disorders, or reproductive
defects or teratogenic effects. There were no signs of loosen-
ing, debonding, or ablation of the graft. Minimal asymptomatic
cartilage hypertrophic changes (<125%) were found in 3
patients, and abnormal cartilage growth was not evident. Nine
patients were subjected to second-look arthroscopy due to
symptoms like persistent grinding, catching, pain, or swelling.
The newly formed repair tissue showed good integration and
bonding as well as a visible contrast in color to the surround-
Figure 1
Arthrotomic implantation of BioSeed®-C. (a) BioSeed®-C was armed 
in each corner with resorbable threads secured by threefold knots. (b) 
In every corner of the defect, k-wires were drilled using the inside-out 
technique. (c) Guiding threads were pulled through the femoral bone 
using the k-wires, and the knots were guided into the subchondral 
bone. (d) The knots serve as anchors, seizing the subchondral bone 
and securely fixing the graft.
Figure 2
Radiographs of patients with focal degenerative cartilage defects prior to treatment with utologous chondrocyte grafts (BioSe d®-C)
to treatment with autologous chondrocyte grafts (BioSeed®-C). (a) 
This patient showed a Kellgren-Lawrence score of 2, with narrowing of 
the joint space (black arrowhead). (b) This patient showed a Kellgren-
Lawrence score of 3, with narrowing of the joint space and osteophytes 
(white arrowheads).Page 4 of 11
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defect site and the retropatellar cartilage were observed. In 2
patients, a new cartilage lesion in the surroundings of the
transplanted area was detected and treated with abrasion
chondroplasty. In two other patients with persistent pain, the
ACI procedure failed and a total knee endoprosthesis was
implanted 4 years after implantation of the graft.
Clinical evaluation of surgical results four years after 
implantation of BioSeed®-C
As assessed by the Lysholm score, statistically significant
improvements (P < 0.05) were observed as early as 6 months
after implantation of BioSeed®-C (Figure 3). Compared with
preoperative findings, the median Lysholm score significantly
improved (P < 0.05), increasing from 55.0 to 89.0 in patients
with focal osteoarthritic degeneration 4 years after implanta-
tion of the graft. The clinical outcome 4 years after implantation
of BioSeed®-C in osteoarthritic focal defects was evaluated
using the IKDC subjective knee evaluation score and the ICRS
score (Figure 4). The IKDC score (Figure 4a) showed signifi-
cant improvement 1 year (P = 0.0068) and 4 years (P =
0.0017) postoperatively compared with the preoperative situ-
ation. The mean score increased from 49.0 to 70.1 after 4
years. In addition, the ICRS score improved significantly (P <
0.05) over the whole study period from 4.0 preoperatively to
2.0 at 4-year follow-up (Figure 4b).
The KOOS describes the patient's view about his knee and
associated problems (Figure 5). At 6-month, 1-year, and 4-
year follow-up, the patients' status improved significantly (P <
0.05) compared with preoperative findings. The median
scores increased in the subclasses pain (69 to 89), activities
of daily living (72 to 96), and knee-related quality of life (25 to
Figure 3
Clinical outcome after four years as evaluated by the Lysholm score. 
Statistical analysis of the clinical outcome as assessed by the Lysholm 
score was performed using analysis of variance on ranks (P < 
0.00001) and subsequently the all-pairwise comparison according to 
Dunn's method. Scores are presented as the median, with the ends of 
the boxes defining the 25th and 75th percentiles and error bars defin-
ing the 10th and 90th percentiles. Where indicated (asterisks), differ-
ences were statistically significant (P < 0.05) compared with the 
preoperative situation.
Figure 4
Clinical outcome after four years as evaluated by the International Knee Documentati n Committee (IKDC) and International Cartilage Repair S ety (ICRS) scor s
Documentation Committee (IKDC) and International Cartilage Repair 
Society (ICRS) scores. (a) Statistical analysis of the clinical outcome 
as assessed by the IKDC subjective knee evaluation score was per-
formed using analysis of variance (P < 0.007) and subsequently the t 
test. Scores are presented as the mean, with error bars defining stand-
ard deviation. (b) The ICRS scores were statistically analyzed by using 
analysis of variance on ranks (P < 0.000001) and subsequently the all-
pairwise comparison according to Dunn's method. Scores are pre-
sented as the median, with the ends of the boxes defining the 25th and 
75th percentiles and error bars defining the 10th and 90th percentiles. 
Where indicated (asterisks), differences were statistically significant (P 
< 0.05) compared with the preoperative situation.Page 5 of 11
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significant improvement in the subclass sports and recreation
(10 to 65) 4 years after implantation, whereas the subclass
symptoms showed no significant improvement (P > 0.05) of
the score (71 to 82). Both patients who needed total knee
replacement after 4 years did not improve in the scores over
the study period (P < 0.05). After 48 months, the Lysholm
score was 38.5 (24 to 53) points and the KOOS subclasses
symptoms and activity of daily life were 41 (38 to 44) points
each and significantly worse compared with the results of the
other patients (P < 0.05).
Magnetic resonance imaging four years after 
transplantation of BioSeed®-C
Two patients had to undergo revision surgery and received a
total knee endoprosthesis. Therefore, 17 out of 19 patients
were analyzed by MRI 4 years after implantation of BioSeed®-
C. Patients with degenerative cartilage defects treated with
BioSeed®-C showed moderate to complete filling of the
defects (Figure 6). Eleven patients showed a complete filling
of the defect with cartilage repair tissue (Figure 6a). In 5
patients, the defects were filled more than 50% (Figure 6b),
and 1 patient showed a defect fill of less than 50% (Figure 6c).
The transosseous drill holes were still visible (Figure 6a,c,
white arrowheads). Representative MRIs as assessed preop-
eratively and at 4-year follow-up (Figure 7) show that cartilage
defects at the medial femoral condyle (Figure 7a,b) and patel-
lar defects (Figure 7c,d) were completely filled with cartilage
repair tissue after transplantation of the graft. A detailed MRI
analysis according to Henderson and Kreuz is given in Table
2. The cartilage signal in 16 out of 17 defects was normal or
showed slight alterations in the intensity. In one defect, the sig-
nal was hyperintense throughout large areas of the repair tis-
sue. Strong to moderate subchondral edema was evident in 6
patients, and 11 out of 17 patients showed no or mild edema.
Five patients showed moderate to strong signs of knee joint
effusion. No to mild knee joint effusion was evident in 12 out
of 17 patients treated with BioSeed®-C at 4-year follow-up.
Both patients who sustained a total knee endoprosthesis after
4 years had the last control MRI after 12 months. The defect
area was partially filled (<50%) with a hyperintensive repair tis-
sue and showed a concomitant moderate subchondral edema.
Discussion
The autologous gel-polymer cartilage graft, BioSeed®-C, uses
the well-known regenerative capacity of autologous chondro-
cytes, gel-like matrices for promoting tissue formation, and the
initial mechanical stability of resorbable polymer scaffolds for
cartilage repair [39]. The assembly of chondrocytes in poly-
mer-based scaffolds ensures the even distribution of a high
number of vital chondrocytes within the graft and has been
shown to allow the production of cartilage grafts that develop
toward hyaline cartilage in vitro [40]. In particular, the embed-
ding of culture-expanded chondrocytes in fibrin and polymer-
based scaffolds made of polyglycolic acid or copolymers of
polyglycolic and polylactic acid initiates chondrocyte re-differ-
entiation in vitro and allows for formation of cartilage matrix in
vivo after implantation of the graft [41,42]. The formation of
cartilage repair tissue after implantation of the polymer-based
graft made of non- and cryo-preserved chondrocytes has been
shown in the rabbit joint defect model [43] as well as in a large
animal horse model. In Haflinger horses, full-thickness carti-
lage defects of the fetlock joint were treated with the autolo-
gous polymer-based cartilage graft, and formation of a hyaline-
like cartilage repair tissue as well as firm bonding of the graft
to the adjacent healthy cartilage and to the subchondral bone
tissue were evident 1 year after implantation [44]. Since the
chondrocytes are embedded in and protected by the fibrin-
Figure 5
Clinical outcome after four years as evaluated by the Knee injury and Osteoarthritis Outcome Score (KOOS). The KOOS is presented as a mean 
value, and error bars define standard deviation. Where indicated (asterisks), differences were statistically significant (P < 0.05) compared with the 
preoperative situation as assessed by the Mann-Whitney rank sum test. ADL, activities of daily living; QoL, quality of life; Sports/Rec, sports and 
recreation.Page 6 of 11
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graft during surgery, avoids the use of cover materials like peri-
osteum or collagen sheets, needs no healthy cartilage rim sur-
rounding the defect, and ensures arthroscopical implantation
and secure fixation [34]. In particular, the secure fixation of car-
tilage grafts is of importance to avoid transplant loosening,
debonding of the graft or ablation, and in turn clinical compli-
cations and re-operations. As assessed in recent biomechan-
ical studies, stable second-generation cartilage grafts for ACI
like BioSeed®-C allow good anchoring of the graft in the
defect by fibrin gluing, chondral or transosseous suturing, and
resorbable pin fixation [45-47]. From the cellular point of view,
particularly in an osteoarthritic environment, joint homeostasis
and the composition of the synovial fluid may be of special
importance in cartilage repair. In a goat model, it has been
shown that defects showed better repair when the lesion was
covered immediately with periosteum compared with defects
that were left untreated before transplantation [48]. Using a
chick limb bud assay, synovial fluid from patients with acute
traumatic cartilage defects has been shown to stimulate chon-
drogenesis, but synovial fluid from patients with chronic trau-
matic defects predominantly inhibited chondrogenic
development [49]. In contrast, synovial fluid obtained from
patients suffering from trauma, osteoarthritis, or inflammatory
rheumatoid arthritis stimulated the synthesis of proteoglycans
in a bovine model, with osteoarthritis and trauma synovial fluid
showing a markedly increased synthesis compared with rheu-
matoid arthritis [50]. In a rabbit model, it has been shown that
synovial fluid promotes and enhances cartilage tissue devel-
opment from perichondrium [51]. Although the influence of
synovial fluid or components of the fluid on cartilage repair
remains unclear and further studies are needed, it is evident
that an altered joint environment may influence tissue regener-
ation. Cartilage repair should be performed as early as possi-
ble and an inflammatory environment should be avoided.
From the clinical point of view, the use of autologous chondro-
cytes in suspension like in first-generation ACI has been
shown to be effective for the repair of localized traumatic
defects [10,11,52]. Second-generation cartilage grafts using
scaffolds based on collagen or hyaluronan for stabilizing autol-
ogous chondrocytes are considered to be technically more
attractive than first-generation ACI and have been shown to be
clinically as effective as 'classical' ACI [22,24]. In a recent
report of the treatment of traumatic and degenerative defects
[26] and in this case series, we demonstrated the safety and
effectiveness of the autologous cartilage gel-polymer graft
BioSeed®-C for the treatment of challenging defects like large
focal degenerative full-thickness cartilage lesions of the knee.
After 1-year follow-up, mean scores increased significantly
between 30% and 51% compared with the preoperative situ-
ation, depending on which score was analyzed. These good
results lasted and showed significant improvement of the
mean scores between 34% and 55% 4 years after implanta-
tion of the graft. This indicates a significant decrease in the
patients' pain and knee instabilities during activity as well as a
significant increase in patients' quality of life. The implantation
of BioSeed®-C in focal osteoarthritic defects showed signifi-
cant improvement in the KOOS subclasses pain, activity of
daily living, and quality of life 1 year and 4 years after implanta-
tion of the graft. Obviously, the efficacy of the polymer-based
autologous cartilage graft BioSeed®-C for the repair of oste-
oarthritic cartilage defects is shown by the improvement of
clinical scores, by patients' pain and quality of life as well as by
the good filling of the defects with repair tissue as assessed
by MRI. This is of special relevance since the BioSeed®-C-
mediated cartilage repair was achieved in a challenging
patient cohort with clinically osteoarthritic symptoms and focal
cartilage degeneration 1 and 4 years after implantation of the
graft. Interestingly, the status of the patient 2 years after ACI is
considered an important indicator for the future outcome. Dur-
ing this time, most of the complications of cell-based cartilage
repair as well as improvement in clinical scores and subjective
patient satisfaction were found. On the other hand, indicators
of a worse outcome like multiple surgical procedures, higher
age, and large defects correspond to findings published by
Figure 6
Magnetic resonance imaging (MRI) four years after implantation of BioSeed®-Cf  r  ft r i l t ti  of io eed®- . (a) Out of 17 patients, 11 patients, including this one, showed com-
plete filling of the defect four years after implantation of BioSeed®-C. (b) Five patients, including this one, showed more than 50% defect filling but 
not complete defect filling. (c) One patient showed less than 50% defect filling (black arrowhead). The repair tissue gives a slightly altered MRI sig-
nal, and transosseous drill holes are still evident (white arrowheads).Page 7 of 11
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clinical outcome of a given treatment strategy, patients' satis-
faction and improvement are most important and are best
assessed by well-established clinical outcome scores. From
the scientific point of view, additional detailed questions arise
regarding measurable parameters like the morphology and
quality of the formed repair tissue, chondrocyte viability and
distribution within the regenerative tissue as well as defect fill-
ing and graft integration. These issues can be addressed by
non-invasive MRI techniques as shown here or by dGEMRIC
(delayed gadolinium-enhanced MRI of cartilage) [54] as well
as by minimally invasive histological evaluation [13,26,55].
These techniques may offer measurable insights in clinical out-
come and value of the graft and may open avenues for devel-
oping precise indicators for the clinical outcome and
prognosis. However, for a comprehensive evaluation of a
regenerative cartilage repair therapy, both approaches are
mandatory, giving clinical scores for patients' satisfaction and
improvement as well as MRI and/or histological analysis for
repair tissue evaluation.
After implantation of BioSeed®-C, 9 out of 19 patients were
subjected to second-look arthroscopy due to symptoms like
grinding, catching, pain, or swelling. This re-intervention rate,
though for diagnostic purposes, is relatively high and may be
related to this challenging patient cohort with a considerable
number of concomitant surgeries like high tibial osteotomy and
anterior cruciate ligament reconstruction. However, only 4 out
of the 19 patients (21%) had to undergo revision surgery or re-
operation. This is in concordance with other studies reporting
rates of revision surgery of between 0% [56] and 25% [20].
Two patients were treated with an abrasion chondroplasty for
newly formed cartilage lesions beside the transplanted area.
Two additional patients out of the 19 patients received a total
knee endoprosthesis and were classified as 'graft failure',
although there is no evidence that the prosthesis was indi-
cated because of a failure of BioSeed®-C. This failure rate of
10% corresponds to earlier findings describing rates of failure
in ACI with other implants of between 5% [12] and 13% [20].
These patients with focal degenerative defects treated with
the chondrocyte graft were young and in the mid to long term
may have no treatment option other than total knee arthro-
plasty. Alternate treatment strategies such as ACI may lead to
several re-interventions and dissatisfied patients but may post-
pone total knee arthrosplasty as possibly the only option for
these patients and are therefore considered a good treatment
for focal degenerative cartilage defects. However, long-term
studies are needed to evaluate whether cell-based cartilage
grafts prevent total joint replacement in osteoarthritis. After 6
months, there was no difference in the scores of these 2
patients with an endoprosthesis and the rest of the study
group. After 12 months, these two patients with a 'graft failure'
had not yet improved and revealed worse results compared
with the other patients. After 12 months or after 48 months,
neither of the 2 patients reached 55 points in the Lysholm
score or 45 points in the IKDC score, indicating that there
might be a threshold for long-term graft survival and success-
ful tissue regeneration. Even if graft regeneration takes a long
time (from 2 to 3 years after surgery), a continuous improve-
ment should be detected 6 to 12 months after surgery. In this
context, the lack of clinical improvement, combined with insuf-
ficient MRI results, may be signs of long-term graft failure. In
general, re-operations and graft failure after implantation of
chondrocytes in a first-generation ACI procedure are caused
by problems associated with the periosteal flap [12,18,57].
This inherent technical disadvantage of the original ACI proce-
dure does not occur when using second-generation ACI grafts
like BioSeed®-C that are void of any cover materials. In addi-
tion, the easy and secure fixation of BioSeed®-C along with
the lack of any covering may reduce the operating time and
may result in a less invasive procedure since there is no need
to harvest periosteum from the tibia. Limitations of the study
are the small number of patients and the lack of a control
group. Since this observational case report study was initiated
first to gain insights in the safety and effectiveness of treating
consecutive cartilage defects with BioSeed®-C, the study is
Figure 7
Magnetic resonance imaging (MRI) before and four years after implan-tatio  of BioSeed®-C
tation of BioSeed®-C. (a) Preoperative MRI shows a cartilage defect 
(encircled) at the medial femoral condyle. (b) After four years, MRI doc-
umented complete filling of the defect. Preoperatively, MRI shows a 
patellar (c) cartilage defect (encircled) that was completely filled after 
implantation of the graft as assessed by MRI at four years (d).Page 8 of 11
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goals. The study was not performed in a randomized control-
led manner in comparison with an appropriate control group or
with an alternate treatment option like microfracturing. Further-
more, in young patients, degeneration of cartilage can be
observed after trauma whereas well-defined osteoarthritis
occurs predominantly in older patients. Therefore, first- or sec-
ond-generation ACI will not be recommended unrestrictedly
for the treatment of focal osteoarthritic cartilage defects. How-
ever, this is the first study showing long-term results using the
second-generation ACI graft BioSeed®-C in patients with
osteoarthritic and/or degenerative changes of the knee. The
study presents a continuous objective patient evaluation
including clinical scores and control MRI over the course of a
period of 4 years.
Conclusions
This extensive case report shows promising results after
implantation of the second-generation autologous cartilage
graft, BioSeed®-C, for the treatment of focal degenerative car-
tilage defects of the knee. Clinical evaluation 4 years after
implantation showed that the treatment of focal osteoarthritic
defects with BioSeed®-C leads to significant improvement of
the patients' condition as documented by reliable clinical out-
come scores and by cartilage regeneration as well as articular
resurfacing as assessed by MRI. The good clinical results
found 1 year after implantation of BioSeed®-C lasted and
remained stable for at least 4 years. Nevertheless, further long-
term studies are needed to evaluate whether cell-based carti-
lage grafts prevent total joint replacement in osteoarthritis.
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